Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial.
Felix MahfoudAhmed FarahMarc-Alexander OhlowNorman MangnerJochen WöhrleSven Möbius-WinklerDaniel WeilenmannGregor LeibundgutFlorim CuculiNicole GilgenChristoph KaiserMarco CattaneoBruno SchellerRaban V JegerPublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2022)
The long-term efficacy and safety of DCB was similar in patients with and without CKD. The use of DCB was associated with significantly fewer major bleeding events (NCT01574534). Central Illustration. Drug-coated balloon versus drug-eluting stents in small coronary artery disease with and without chronic kidney disease, a prespecified subgroup analysis of the BASKET-SMALL 2 trial.
Keyphrases
- coronary artery disease
- chronic kidney disease
- phase iii
- end stage renal disease
- clinical trial
- study protocol
- percutaneous coronary intervention
- phase ii
- atrial fibrillation
- cardiovascular events
- cardiovascular disease
- coronary artery bypass grafting
- adverse drug
- randomized controlled trial
- drug induced
- left ventricular
- aortic valve
- transcatheter aortic valve replacement